P1.03-23 the Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

X. Chen,C. Xu,W. Wang,Q. Zhang,W. Zhuang,Y. Zhu,Y. Chen,M. Fang,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.704

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:The identification and clinical validation of cancer driver genes are essential to accelerate the translational transition of cancer genomics, as well as to find clinically confident targets for the therapeutic intervention of cancers. While the genetic variability of neurotrophic receptor tyrosine kinase 1 (NTRK1) mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring NTRK1 mutations. A total of 389 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of NTRK1 mutation and other genes were detected by next generation sequencing. NTRK1 gene mutation rate was 4.11% (16/389) in non-small cell lung cancer, including H268Q (1 patient), V181M (1 patient), Q459R (1 patient), G726C (1 patient), R89H (1 patient), M635I (1 patient), L126Q (1 patient), G138R (1 patient), E245A (1 patient), M530T (1 patient), L549Cfs*73 (1 patient), N293S (1 patient), E245A (1 patient), W236C (1 patient), E456K (1 patient) and F297L (1 patient), and median overall survival (OS) for these patients was 11.0 months. Among them, all patients were NTRK1 gene with co-occurring mutation. Briefly, patients with (n=5) or without (n=11) co-occurring EGFR mutations had a median OS of 14.0 months and 11.0 months respectively (P=0.90); patients with (n=12) or without (n=4) co-occurring TP53 mutations had a median OS of 11.0 months and 6.0 months respectively (P=0.67); patients with (n=3) or without (n=13) co-occurring BRAF mutations had a median OS of 14.0 months and 11.0 months respectively (P=0.43); patients with (n=4) or without (n=16) co-occurring CDKN2A mutations had a median OS of 3.5 months and 14.0 months respectively (P<0.01). NTRK1 oncogenic activation through gene fusion defines a novel and distinct subset of NSCLC. EGFR, TP53 and BRAF gene accompanied may have less correlation with KIT mutation in NSCLC patients. CDKN2A accompanied mutations might play a worse prognosis in NTRK1 gene mutation non-small cell lung cancer.